Here, after controlling for potential confounders, we found that EPO use of less than 71 annual DDDs, 71–200 annual DDDs, and over 201 annual DDDs in cumulative dose is associated with a 28%, 47%, and 38% risk reduction in dementia, respectively, as compared with not using EPO. The gene discussed is EPO; the disease is dementia.